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INTRODUCTION
Staphylococcus aureus is a bacterial pathogen dis-
tributed worldwide and a leading cause of mor-
bidity and mortality. It causes a variety of infec-
tions ranging in severity from mild to severe, life-
threatening conditions (Miller et al., 2005). The
pathogenicity of S. aureus is related to an ex-
haustive arsenal of virulence factors and toxins.
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In particular, Panton-Valentine leukocidin (PVL),
a cytotoxin causing leukocyte destruction and tis-
sue necrosis, is known to be a stable marker of
community-acquired MRSA strains (Vandenesch
et al., 2003). PVL-producing strains are typically
associated with severe skin and soft tissue infec-
tions (SSTIs) and necrotizing pneumonia (Miller
et al., 2005; Durupt et al., 2007). 
Further issues of concern are the ability of S. au-
reus to acquire antibiotic resistance, and its emer-
gence and dissemination outside of the health-
care setting. Since the first appearance of methi-
cillin-resistant S. aureus (MRSA) in healthcare
facilities 50 years ago, several epidemiological
changes have affected this pathogen, beginning
with resistance to non β-lactam antibiotics until
the more recent involvement in community in-
fections (Chambers and DeLeo, 2009). Since the
Methicillin-resistant Staphylococcus aureus (MRSA) is a major antimicrobial drug-resistant pathogen causing serious
infections. It was first detected in healthcare settings, but in recent years it has also become disseminated in the com-
munity. Children and young adults are most susceptible to infection by community-acquired (CA) MRSA strains. In
this study 25 MRSA isolates implicated in infections of neonates and children admitted to an Algiers hospital during
an 18 month period were characterized by molecular methods including staphylococcal cassette chromosome (SCC)
mec typing, PCR amplification of pvl genes, pulsed field gel electrophoresis (PFGE) and multilocus sequence typing
(MLST). Fifteen out of 25 isolates were from hospital-acquired infections. Twenty-four isolates carried SCCmec type
IVc and belonged to the sequence type (ST) 80, one isolate carried SCCmec type II and was ST 39. Twenty-two out of
24 ST80-MRSA-IVc isolates carried pvl genes. Our results suggest that the Panton-Valentine leukocidin positive ST80-
MRSA-IVc is the dominant MRSA clone causing disease in neonates and children in Algiers.
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first report of cases of MRSA infections in previ-
ously healthy young people, community-acquired
(CA)-MRSA strains have been increasingly re-
ported worldwide (Vandenesch et al., 2003). In
recent years, a progressive blurring of boundaries
between hospital-acquired (HA)-MRSA and CA-
MRSA infections was first anticipated and then
described in several countries (Saiman et al.,
2003; Skov and Jensen, 2009). Previous studies
have reported high rates of MRSA infection in
Algeria both in community and healthcare facil-
ities. The most prevalent clone is described to be
ST80, carrying pvl genes and a SCCmec IV ele-
ment (Antri et al., 2011). Other clones have also
been reported, but usually within the hospital set-
ting. 
The aim of this study was to describe the molec-
ular and epidemiological features of MRSA
strains involved in infections of children and new-
borns in an Algiers hospital.
MATERIALS AND METHODS
Patients and MRSA strains 
The “Mother and Child” central laboratory of
Beni-Messous University hospital in Algiers is
dedicated to microbiological investigations con-
cerning perinatal and pediatric transmissible dis-
eases. All MRSA strains implicated in infections
of neonates and children were collected during
the 18 month period April 2010-September 2011.
Information including gender, age, site of isola-
tion and diagnosis was collected. For the pur-
poses of this study, MRSA strains isolated from
outpatients or, alternatively, from inpatients with-
in 48 hours after their admission were identified
as community-onset (CO)-MRSA, whilst those
isolated more than 48 hours after admission were
considered HA-MRSA. Strain identification was
based on colony morphology on Mannitol salt
agar (OXOID, Basingstoke, UK), production of
coagulase by using rabbit plasma (OXOID) and
Staphyslide agglutination tests (BioMérieux,
Marne-La-Coquette, France). Methicillin resist-
ance was screened by subculturing the isolates
on Müller Hinton agar with 4% NaCl and 6 µg/ml
of oxacillin and confirmed by testing resistance to
cefoxitin by the disk diffusion method, according
to the Clinical Laboratory Standards Institute
(CLSI, 2011).
Antimicrobial susceptibility testing
Susceptibility of the MRSA strains was tested
against 11 antimicrobial agents using the disk dif-
fusion method according to the Clinical
Laboratory Standards Institute (CLSI, 2011). The
antibiotics tested were ciprofloxacin (5 µg), clar-
ithromycin (15 µg), clindamycin (2 µg), erythro-
mycin (15 µg), gentamicin (10 µg), linezolid (30
µg), rifampicin (5 µg), tetracycline (30 µg), te-
icoplanin (30 µg), trimethoprim-sulfamethoxa-
zole (1.25/23.75 µg) and vancomycin (30 µg). 
SCCmec typing and type IV SCCmec
subtyping
All strains were cultured on brain heart infusion
broth and incubated at 37°C overnight, and then
DNA was extracted according to standard proto-
cols (Kostman et al., 1992). Multiplex PCR was
performed to identify the SCCmec types I to VI
with the mecA gene as a positive control
(Milheiriço et al., 2007a). PCR products were then
visualized on 3% TBE-agarose gels. To distinguish
between the different SCCmec IV subtypes, a fur-
ther multiplex PCR was performed as previously
described (Milheiriço et al., 2007b).
Panton-Valentine leukocidin genes detection
The presence of the pvl genes, lukS-PV and lukF-
PV, was detected as described previously (Said-
Salim et al., 2005). PCR products were resolved by
electrophoresis on 1.5% agarose gel.
Multiple loci variable number tandem
repeat fingerprinting (MLVF)
MLVF typing was performed according to the
procedure described by Sabat et al. (2003).
Electrophoresis was performed in 0.5X Tris-bo-
rate buffer-2% agarose gels. Banding patterns
were visually compared and those differing by at
least one band considered different.
Pulsed field gel electrophoresis (PFGE)
fingerprinting
MRSA isolates representative of the different
MLVF profiles were submitted to PFGE after
SmaI macrorestriction of genomic DNA as de-
scribed previously (Mulvey et al., 2001). DNA frag-
ments were separated by CHEF Mapper® (Bio-
Rad Laboratories, Hercules, CA, USA), and ana-
lyzed by BioNumerics software version 6.5
(Applied Math, St-Martin-Latem, Belgium).
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MultiLocus sequence typing (MLST)
MLST was performed on strains representative
of the different PFGE profiles as previously de-
scribed (Enright et al., 2000). Seven housekeeping
genes were sequenced to determine the allelic
profile. Strains were assigned to a sequence type
(ST) using the MLST database (http://saureus.
mlst.net/).
RESULTS 
Patient characteristics
During the 18 month period of study, 25 strains
of MRSA and 104 of MSSA were isolated from as
many cases of infection in neonates and children.
Ten MRSA strains were isolated from outpatients
or inpatients within 48 hours after their admis-
sion and categorized as CO-MRSA. 
The remaining 15 isolates were recovered from
hospitalized patients from 48 hours after admis-
sion onwards and defined as HA-MRSA (Table
1). The median age was 74 months (ranging from
7 days to 15 years). 
Eight patients were aged two years or less, nine
2-10 years, and eight 10-15 years. Male gender
was more prevalent than female with an M/F ra-
tio of 1.78 (Table 1). The clinical characteristics of
the infection cases are summarized in Table 1.
Most isolates - 15 out of 25 - were implicated in
SSTIs and five further isolates in bone and joint
infections. Six out of 10 CO-MRSA were impli-
cated in SSTIs, whereas the three MRSA strains
identified from bacteremia cases were all hospi-
tal-acquired (Table 1).
Antibiotic susceptibility patterns
Nineteen strains (76%) were resistant to tetracy-
cline, eight to clarithromycin, seven to erythro-
mycin, four to ciprofloxacin and three to clin-
damycin. No resistance was detected towards
gentamicin, rifampicin, trimethoprim-sul-
fomethoxazole, vancomycin, teicoplanin or line-
zolid. Antibiotic resistance patterns are illustrat-
ed in Table 1.
Molecular characterization of isolates
Among the 25 MRSA isolates under study,
SCCmec IV was found in 24 and SCCmec II in
the remaining isolate (Figure 1). Subtyping of
SCCmec IV disclosed the subtype IVc in all 24 iso-
lates, of which 22 tested positive for pvl genes.
The two PVL negative S. aureus isolates carrying
SCCmec IVc were CO-MRSA, the first causing
osteomyelitis and the second SSTI. The isolate
with SCCmec II was a CO-MRSA implicated in
SSTI, and tested pvl negative. 
By MLVF typing 23 different patterns were de-
tected. PFGE was then performed on these 23
isolates: 22 of them showed closely related pat-
terns differing between each other by less than
three bands with more than 85% similarity. The
last isolate showed an unrelated pattern (Figure
1). MLST typing assigned all MRSA strains but
one to ST80. The remaining PVL negative strain,
carrying SCCmec II, was attributed to ST39.
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TABLE 1 - Characteristics and resistance patterns
of 15 Hospital-Acquired and 10 Community-Onset
Methicillin-Resistant S. aureus recovered from
patients admitted to Beni-Messous Hospital,
Algiers, 
from April 2010 to September 2011.
MRSA strains HA-MRSA CO-MRSA Total
15 10 25
Patients characteristic
Median age 74 months
7 days-2 years 5 3 8
2-10 years 6 3 9
10-15 years 4 4 8
M/F ratio 1.78
Female 6 3 9
Site of infection
SSTI infections 9 6 15
Bone/joint infection 1 4 5
Bacteraemia 3 0 3
Otitis 1 0 1
Other 1 0 1
Antibiotic resistance 
to non β-lactams
None 2 2 4
TE 8 3 11
TE, CIP 1 1 2
TE, E, CLR 3 0 3
TE, CIP, CLR 0 1 1
TE, E, CLR, CIP, DA 1 1 2
E, CLR 0 1 1
E, CLR, DA 0 1 1
CO-MRSA: community onset MRSA, HA-MRSA: hospital acquired MRSA,
SSTI: skin and soft tissue infections, TE: tetracycline, CIP: ciprofloxacin, E:
erythromycin, CLR: clarithromycin, DA: clindamycin.
DISCUSSION
Infections by MRSA, especially by community-
associated PVL-producing clones are increasing-
ly reported worldwide (Vandenesch et al., 2003).
In the USA, the rapid emergence of CA-MRSA as
a cause of invasive and noninvasive infections in
children and young people has always reached
epidemic proportions (Purcell et al., 2005). MR-
SA infections also appear to be increasing in new-
borns and infants (Fortunov et al., 2006).
In Algeria, high MRSA rates in community and
healthcare setting have been reported with ST80-
MRSA-IV being the most prevalent clone
(Ramdani-Bouguessa et al., 2006; Antri et al.,
2011). However, no study has been carried out on
children and infants. Hence, our main interest
was to assess the molecular characteristics of
MRSA strains implicated in infections of these
subjects. During the 18 month period of study, 10
of the 25 MRSA strains were epidemiologically
attributable to CO-MRSA. Similar results have
been reported by previous studies in Algeria
(Ramdani-Bouguessa et al., 2006; Antri et al.,
2011) and throughout the world, confirming the
upward trend of infections caused by CA-MRSA
strains in hospital (Herold et al., 1998). In other
studies, CA-MRSA infection cases have already
exceeded hospital-acquired infections (Liu et al.,
2008). Indeed, a clinical onset in the hospital set-
ting does not rule out a community source, CA-
MRSA most likely being carried in the upper res-
piratory tract or various cutaneous and mucosal
sites and brought into the hospital by the nursing
staff, the patients themselves or their caregivers
(Saiman et al., 2003; Skov & Jensen, 2009). 
Eight of the 25 patients under study were less
than two years old. In a three-year study at Texas
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FIGURE 1 - Dendrogram of the electrophoretic patterns of DNA macrorestriction by SmaI of 23 MRSA isolates,
Algiers 2011. CO-MRSA, community onset MRSA; HA-MRSA, hospital acquired MRSA; pvl, Panton-Valentine leu-
cocidine sequence; ST: sequence type.
Children’s Hospital, about half the children with
CA-MRSA infections were aged 2 years old or less
(Kaplan et al., 2005). Similarly, according to pre-
vious reports, the male gender was more preva-
lent (Fortunov et al., 2006; Liu et al., 2008;
Shallcross et al., 2010; Edelstein et al., 2011). In
this regard it has been speculated that some gen-
der-specific physical factors might predispose to
infection, but this has not been confirmed in
younger subjects (Shallcross et al., 2010).
Moreover, in agreement with the findings of oth-
er authors, SSTIs are the most frequent type of in-
fection. 
The MRSA strains exhibited a low prevalence of
resistance to non beta-lactam antibiotics, consis-
tent with the characteristics described for the
ST80-MRSA clone (Chua et al., 2011). However,
spilling of this community clone into the health-
care setting might constitute an important step
towards the emergence and spread of more re-
sistant strains, as is the case for the clindamycin
and ciprofloxacin-resistant strains identified in
this study and reported by other authors (Antri
et al., 2011; Vergison et al., 2011).
Of the 25 MRSA isolates 22 harbored PVL genes.
In previous studies on the general population in
Algeria, rates of PVL-producing strains were
29.7% (Ouchenane et al., 2011), 35.7% (Antri et
al., 2011) up to 67.2% (Ramdani-Bouguessa et al.,
2006). High rates of PVL-producing MRSA were
also reported in other countries such as the US
and Tunisia (Fortunov et al., 2006; Ben Nejma et
al., 2008). On the contrary, lower rates or no PVL-
positive MRSA were reported in other countries:
15% in the Netherlands (Adedeji et al., 2007),
0.7% in a nationwide study in Japan (Yanagihara
et al., 2012), near to zero in some English hospi-
tals (Shallcross et al., 2010). 
ST80-MRSA-IV is the most widespread clone in
Algeria (Ramdani-Bouguessa et al., 2006; Antri
et al., 2011). However, our report first detected
it as the predominant strain among pediatric cas-
es of infection, with a similar prevalence to that
described for the USA300 clone in the USA.
ST80-MRSA is also frequently detected in North
African and Middle East countries such as
Tunisia (Ben Nejma et al., 2008) and Kuwait
(Udo & Sarkhoo, 2010). In Egypt, this clone was
not dominant and appeared to be largely sus-
ceptible to antibiotics (Enany et al., 2010). In
many European countries, such as Denmark
(Larsen et al. 2008), Belgium (Denis et al., 2005)
and Switzerland (Francois et al., 2008), ST80-
MRSA seems to be quite sporadic and many cas-
es are associated with travel histories in
Mediterranean and Middle East countries
(Larsen et al. 2008). The PVL negative ST39-MR-
SA-II isolate, belonging to CC30, is attributable
to EMRSA-16. Emergence and epidemic dis-
semination of this clone, along with ST22-MR-
SA-IV (EMRSA-15), was correlated with the rise
in some European countries of MRSA in the
1990s and early 2000s. However, the proportion
of EMRSA-16 was declining from the late 1990s
(Ellington et al., 2010). Other members of CC30
have been reported in Algeria (Ramdani-
Bouguessa et al., 2006).
We here report that PVL positive ST80-MRSA-
IVc is the leading MRSA clone among children
and neonates in Algiers. Moreover, it appears not
only to cause community-onset infections, but is
also as an emerging cause of healthcare-associ-
ated infections. Special attention is required in
diagnosing and treating MRSA infections in pe-
diatric patients in order to prescribe appropriate
antibiotic therapeutic regimens, adequately con-
trol the possible severe complications and pre-
vent the dissemination of this pathogen.
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